Cardiac Biomarkers in Stroke, Alzheimer’s Disease, and Other Dementia. Are They of Use? A Brief Overview of Data from Recent Investigations

Author(s): Shahzad Khan*, Mohammad Amjad Kamal

Journal Name: CNS & Neurological Disorders - Drug Targets
Formerly Current Drug Targets - CNS & Neurological Disorders

Volume 20 , Issue 8 , 2021

Become EABM
Become Reviewer
Call for Editor


Conventionally, cardiac biomarkers are recognized as an essential tool to investigate the presence or progression of various cardiovascular diseases. However, in recent years, data from several clinical trials have successfully sorted out the utility of cardiac biomarkers in diseases that are not primarily regarded as “cardiac diseases,” especially neurological diseases. Results of freshly published trials have endorsed the use of cardiac biomarkers in various forms of stroke and dementia, including Alzheimer’s disease. Alzheimer’s disease is also one of the other CNS conditions where measuring cardiac biomarkers have been found to be useful. Cardiac biomarkers can be helpful in two ways. Firstly, to assess the secondary involvement of the heart during the progression of the primary disease. Secondly, they can be useful in the diagnosis and prognosis of the primary condition itself. In this short review, we have collected encouraging results from recent studies that show the importance of the most widely recognized cardiac biomarkers in two of the most prominent neurological diseases of the current world, i.e., stroke and dementia.

Keywords: Cardiac biomarker, BNP, troponin, Alzheimer's disease, stroke, pneumonia.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 05 October, 2020
Page: [687 - 693]
Pages: 7
DOI: 10.2174/1871527319666201005171003
Price: $65

Article Metrics

PDF: 444